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Abstract
Background—Oxidative stress, an excessive production of reactive oxygen species (ROS)
outstripping antioxidant defense mechanisms, occurs in cardiovascular pathologies including
hypertension. Here, we used biochemical, physiological, and pharmacological approaches to
explore the role of derangements of catecholamines, ROS, and NO• in the development of a
hyper-adrenergic model of hereditary hypertension: targeted ablation (knockout, KO) of
chromogranin A (Chga) in the mouse.
Methods and Results—Homozygous (−/−) Chga gene knockout (KO) mice were compared to
wild-type (WT, +/+) controls. In the KO mouse, elevations of systolic and diastolic BP were
accompanied by not only elevated catecholamine (norepinephrine and epinephrine)
concentrations, but also increased ROS (H2O2) and isoprostane (an index of lipid peroxidation), as
well as depletion of NO•. Renal transcript analyses implicated changes in Nox1/2, Xo/Xdh, and
Sod1,2 mRNAs in ROS elevation by the KO state. KO alterations in BP, catecholamines, H2O2,
isoprostane, and NO• could be abrogated or even normalized (rescued) by either sympathetic
outflow inhibition (with clonidine) or NADPH oxidase inhibition (with apocynin). In cultured
renal podocytes, H2O2 production was substantially augmented by epinephrine (likely through b2-
adrenergic receptors) and modestly diminished by norepinephrine (likely through a1-adrenergic
receptors).
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Conclusions—ROS seem to play a necessary role in the development of hyper-adrenergic
hypertension in this model, in a process mechanistically linking elevated BP with catecholamine
excess, renal transcriptional responses, ROS elevation, lipid peroxidation, and NO• depletion.
Some of the changes seem to be dependent on transcription, while others are immediate. The cycle
could be disrupted by inhibition of either sympathetic outflow or NADPH oxidase. Since common
genetic variation at the human CHGA locus alters BP, the results have implications for
antihypertensive treatment as well as prevention of target-organ consequences of the disease. The
results document novel pathophysiological links between the adrenergic system andc oxidative
stress, and suggest new strategies to probe the role and actions of ROS within this setting.
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Introduction
Increased sympathoadrenal activity plays a role in the development or maintenance of
elevated blood pressure in both hypertensive patients and animal models of hypertension1–4.
Chromogranin A (CHGA human, Chga rodent), the index member of the chromogranin/
secretogranin protein family, is co-stored and co-released with catecholamines from
secretory vesicles in adrenal medulla5–7 and post-ganglionic sympathetic axons8. Although
CHGA is over-expressed in human essential (hereditary) hypertension, the plasma
concentration of its catestatin (catecholamine release-inhibitory) fragment9 is decreased in
not only established cases of hypertension, but also still-normotensive subjects with a family
history of hypertension10, 11. Genetic variation at the human CHGA locus predicts
substantial alterations in BP12–14. Expanding upon the human findings, we found that Chga
knockout (KO, −/−) mice are hypertensive and hyper-adrenergic15. To get a better insight
into the development of hypertension in KO mice we looked at the status of reactive oxygen
species (ROS) and nitric oxide (NO) in these mice.
Oxidative stress, characterized by excessive production of reactive oxygen species (ROS)
outstripping antioxidant defense mechanisms, has been associated with several
cardiovascular pathologies including hypertension16, 17, hypercholesterolemia, and diabetes.
ROS are a family of short-lived, highly reactive byproducts of oxygen (O2) metabolism.
They include oxygen ions, free radicals, and peroxides, both inorganic and organic. ROS are
generated by O2 metabolism through NADH dehydrogenase in mitochondria, as well as by
specific oxidases, including NADPH oxidase (Nox), xanthine oxidase (Xdh/Xo) and
arachidonic acid (AA)-metabolizing enzymes18. ROS may promote vascular smooth muscle
cell contraction and proliferation, enhancing contraction in part by depleting the
endothelium derived relaxing factor nitric oxide (NO•)19.
In animal models, oxidative stress has been observed in the spontaneous (genetically)
hypertensive rat20, renovascular hypertension21, salt-sensitive hypertension22, and obesity-
induced hypertension23. Although its pathogenesis is complex, human hypertension also
displays signs of increased oxidative stress16, 17, 24, 25, associated with a decreased
antioxidant activity and a reduced ability to scavenge oxygen-derived free radicals26, 27.
Indeed, enhanced ROS accumulation may be a heritable trait in hypertensive pedigrees17,
with penetrance even before the onset of overt hypertension16.
In the present study, we explore the involvement of ROS and NO• in the development of a
hyper-adrenergic model of hereditary hypertension: the Chga-KO mouse. Our results
suggest a role for catecholamine excess in generating a hypertensive state partially
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consequent upon ROS activation and NO• depletion, a state amenable to pharmacological
correction by inhibition of either adrenergic outflow or ROS generation.
Methods
Targeted ablation of the Chga locus in the mouse
Mice were studied according to a protocol approved by the Animal Subjects Committee of
the University of California at San Diego, and research was conducted in accordance with
institutional guidelines. Ablation of Chga gene was done as described previously15. The
homozygous (−/−) Chga gene knockout (KO) mouse line was maintained and used for the
experiments, and compared with wild-type (WT, +/+) strain controls; 5–6 month-old
animals were studied from each strain. Based upon preliminary calculations of statistical
power for BP, a threshold number of animals was included in each study, but we used as
many animals as were available at each step from our local breeding colony (as many as 10–
12), to optimize our ability to find true positive and avoid false negative results.
Renal podocyte cultures
Since we found ROS changes in urine and kidney during hyper-adrenergic hypertension, we
studied ROS generation by kidney podocytes, as a renal cell type in contact with urine as it
is generated in Bowman's space. Conditionally immortalized mouse podocytes were a gift of
Peter Mundel, and were cultured at 33°C in the presence of IFN-γ as previously described28
for multiplication purposes, in the presence of mouse gamma interferon for 7 days until the
cells reached 90% confluence. Podocytes were trypsinized at this point and split at 1:5 ratio
for differentiation at 37°C for 8–10 days without IFN-γ in DMEM containing 5.5 mmol/L
glucose and 5% FCS. Differentiated podocytes were serum-starved overnight when
confluent, and then used for the experiments.
Biochemical measurements: Catecholamines, H2O2, isoprostane, creatinine, nitric oxide
(NO•)
Catecholamines—Catecholamines were measured in mouse plasma from anesthetized
animals by high performance liquid chromatography (HPLC) (Waters 600E Multisolvent
Delivery System; Waters, Milford, MA) using an electrochemical detector (ECD) (Waters
2465 Electrochemical Detector). Sample purification was done using activated alumina. The
data were analyzed using Empower software from Waters, and catecholamine levels
normalized according to the recovery of internal standard 3,4-dihydroxybenzylamine
(DHBA) as previously described15.
H2O2—As a quantitative index of H2O2 generation, fluorescence generated by the Amplex
Red reagent [10-acetyl-3,7-dihydroxyphenoxazine; Amplex Red Hydrogen Peroxide/
Peroxidase Assay Kit, Molecular Probes (A-22188); Invitrogen, Carlsbad, CA] was
monitored. Amplex Red reacts with hydrogen peroxide in the presence of horseradish
peroxidase (HRP) with 1:1 stoichiometry to form the fluorophore resorufin. Amplex Red
and peroxidase in Kreb's Ringer phosphate buffer (pH 7.4) were introduced into each well
(podocyte or urine) in the dark. Catecholamines (epinephrine or norepinephrine) or synthetic
adrenergic agonists (alpha-1: phenylephrine; alpha-2: clonidine; beta: isoproterenol) were
tested for effects on H2O2 production in podocytes. The contents of the plate were incubated
at 37°C for 60 min before the commencement of the first cycle of measurement.
Fluorescence intensity of resorufin was kinetically recorded with excitation at 544 nm and
emission of 590 nm at 37°C, via fluorescent plate reader (POLARstar OPTIMA; BMG
Labtech, Offenburg, Germany). Measurements were made over 10–20 cycles, at 19–67 sec/
cycle. The data are reported as the mean value from each well over the recording period,
with n=6 wells per experimental condition. H2O2 levels were also measured in mouse urine,
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and then normalized by urine creatinine values, or in kidney cortex homogenate, with
normalization to protein concentration in the same sample.
Nitric oxide—Urine or plasma nitric oxide (NO•) was measured according to
manufacturer's protocol using a colorimetric assay kit for conversion of nitrate → nitrite by
nitrate reductase, followed by quantification of nitrite with the Griess reaction and
absorbance at 540 nm (Cayman Chemical, Ann Arbor, MI). Urinary NO• levels were
normalized by urine creatinine values, or in kidney cortex homogenate, with normalization
to protein concentration in the same sample.
Isoprostane—As an index of systemic oxidative stress, we used the urinary content of 8-
iso-PGF2α (also known as 8-epi-PGF2α, or 15-isoprostane F2t) a stable product of
arachidonic acid formed on non-enzymatic oxidation. Urinary isoprostane was measured
using an ELISA kit (Northwest Life Science Specialties LLC, Vancouver, WA). The assay
sensitivity was 50 pg, with a dynamic range of 0.1–10 ng/ml, and the average intra-assay
coefficient of variation for 24 replicate samples was 1.72%. Cross-reactivities were
undetectable (<0.01%) for prostaglandins F2α, E2, D2, or arachidonic acid. The correlation
between this ELISA method and GC/MS was r=0.89. Urinary isoprostane levels were
normalized by urine creatinine values.
Creatinine—Diluted urine samples (0.5 mL) were mixed with 6 ml water and 1 ml
saturated alkaline picrate solution. The mixture was kept for 45 min at 20°C, absorbance
measured at 505 nm and calculated using known standard concentrations.
Blood pressure
BP of mice was measured by the non-invasive tail-cuff method using the BP-2000 Blood
Pressure Analysis System (Visitech Systems, Apex, NC <http://www.visitechsystems.com/
>), as previously described15. Mice were placed into individual rodent restraint holders on a
preheated specimen platform at 38°C as measured by a LCD strip thermometer. For each
treatment state, BP was measured at three sessions daily, between 1 PM to 3 PM, for 5
consecutive days (Mon→Fri). The first 2 days (Mon/Tues) were for acclimation of mice
with the BP system, while data from the last 3 days (Wed/Thurs/Fri) were analyzed. At each
of the 3 daily sessions, BP was measured 10 times in succession (with Visitech hardware/
software), and the results were averaged and saved as one measurement (with standard
deviation) in a notebook computer running the BP analysis software package (Visitech
Systems) via a PCMCIA data acquisition card. As per the manufacturer's protocol, BP
readings having a standard deviation of less than 10 mmHg were accepted for further
analysis. We thus collected 9 measurements (3 days; 3 measurements/day) at each state for
each mouse. Elevations of BP in the Chga(−/−) mouse can be detected by either this non-
invasive method, or by implanted carotid transducers with telemetric monitoring15.
Drug treatments
Inhibition of sympathetic outflow—Clonidine HCl (C7897 at >98% purity by TLC;
Sigma-Aldrich, St. Louis, MO) was embedded in a clonidine-chow diet for rodents by
Harlan-Teklad (Madison, WI), beginning with 1% (w/w) clonidine HCl in sucrose, and
embedding in Harlan formula 5001 standard laboratory rodent diet, at 1 mg/kg chow. The
dose was calculated to achieve delivery of 125 μg clonidine/kg body weight/day, and used
for 3 weeks.
Inhibition of NADPH oxidase—Apocynin (acetovanillone, A10809 at 98% purity;
Sigma-Aldrich, St. Louis, MO) was used at 2 mmol/L in drinking water for 3 weeks.
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mRNA abundance by real-time RT-PCR
Total RNA was extracted form one kidney of each mouse and real-time PCR was done with
fluorescent reporter-tagged oligonucleotide primers on an ABI-7700 TaqMan platform (Life
Technologies, Carlsbad, CA), with normalization of data to β-actin expression. Ct (threshold
cycle) is determined for both the specific target mRNA/cDNA as well as β-actin, and the
difference in Ct (from target mRNA versus β-actin mRNA) is normalized to the average for
that state (e.g., control versus experimental), and expressed on a % change (difference)
scale.
Renal cortex biochemistry
Renal cortical homogenates were prepared from freshly harvested adult male kidneys (WT
and KO), and assayed for H2O2 and NO•, as described above. Results were normalized to
homogenate protein concentration (Bradford Coomassie Brilliant Blue R-250 assay method;
BioRad, Hercules, CA).
Mitochondrial electron transport chain
Mitochondria were prepared from freshly harvested adult male livers (n=3 WT, n=3 KO), as
described29. Overall mitochondrial mass (per mg tissue protein) was indexed by citrate
synthase activity, and electron transport chain enzymatic activity of mitochondrial
complexes I, II, II/III, and IV was determined and normalized to citrate synthase activity as
described29.
Statistical analyses
Results are expressed as the mean value ± one SEM (standard error of the mean). The
reported “n” refers to the number of mice, rather than to the number of BP measurements
taken (since, under each condition, BP was measured multiple times in each mouse, and then
averaged for that mouse). Data were evaluated by ANOVA, followed by post hoc tests, in
Excel (Microsoft, Bellevue, WA), Kaleidagraph (Synergy Software, Reading, PA) or
SPSS-17 (Chicago, IL). MANOVA (multivariate ANOVA) was used to test the effect of
strain on more than one dependent variable. Repeated measures (e.g., multiple BP values for
each animal at each treatment state) were approached by linear mixed effect models
(MIXED) in SPSS-17, to account for correlated data, factoring also for treatment. P values
less than 0.05 were considered statistically significant.
Results
Chga ablation on H2O2 and lipid peroxidation (isoprostane) in urine and kidney
Since increased ROS activity generates H2O219, 30 with resulting lipid peroxidation
(isoprostane)31, we measured H2O2 and isoprostane renal excretion, as well as H2O2 in
kidney. Chga ablation caused significant increases in both urinary H2O2 and isoprostane
excretions (Fig. 1A). There was a ~20% increase in urinary isoprostane excretion in KO
mice (10.33±0.51 vs 12.86±0.61 ng/mg creatinine, p<0.02) (Fig. 1A), while urinary H2O2
excretion was ~2.5 times higher in the KO mice (1851.6±256.6 vs 4574.7±306.6
fluorescence units/mg creatinine, p<0.002) (Fig. 1A). MANOVA confirmed the
simultaneous effect of mouse strain on the two oxidative traits (p<8.55E-06). In renal cortex,
H2O2 was elevated by ~45% in the KO (on-line Fig. 1).
Catecholamines on H2O2 in cultured glomerular podocytes
Epinephrine caused a substantial increase (p<0.001) in H2O2 production, while
norepinephrine caused a modest decrease (also p<0.001) (Fig. 1B). When adrenergic
receptor type-specific agonists were tested (Figure 1C), both the alpha-1 agonist
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phenylephrine (p<0.001) and the alpha-2 agonist clonidine reduced H2O2, while the beta
agonist isoproterenol substantially increased H2O2 (p<0.001). Since epinephrine displays
preferential activity at beta-2 receptors, epinephrine likely increases H2O2 production via
beta-2 activation32; since norepinephrine displays preferential activity at alpha-1 over
alpha-2 receptors, norepinephrine likely inhibits H2O2 production via alpha-1 activation32.
Sympathetic outflow inhibition (clonidine) on BP
Chga ablation caused substantial elevations of both systolic (p<0.0001) and diastolic
(p<0.003) BP15 (Fig. 2). 3 weeks of sympatho-inhibitory treatment with the α2-adrenergic
agonist clonidine caused significant reductions of both SBP (by ~9.1 mmHg; from
139.3±1.8 to 130.2±2.7 mmHg, p<0.02) and DBP (by ~9.9 mmHg; from 101.1±2.6 to
91.2±3.3 mmHg, p<0.03) in the KO mice (Fig. 2), and the effects on DBP virtually
normalized the trait.
NADPH oxidase (Nox) inhibition (apocynin) on BP
After treatment of the KO with the NADPH oxidase inhibitor apocynin for 3 weeks, SBP
was reduced by ~10.9 mmHg (from 139.3±1.8 to 128.4±2.0 mmHg, p<0.001) while DBP
fell by ~11.2 mmHg (from 101.1±2.6 to 89.9±2.5 mmHg, p<0.007) (Fig. 2), and the effects
on DBP virtually normalized the trait.
BP repeated measures
At each state (strain, treatment), BP was analyzed from 9 sets of measurements in each
animal (3 days, 3 times/day). To account statistically for correlated values during repeated
BP determinations, we also used a linear mixed effect model, specifying random effect per
mouse. Treatment effects on SBP (F=40.3, p=2.8E-11) and DBP (F=11.9, p=1.7E-7)
remained significant. Repeated measures ANOVA also yielded significant effects for
treatment regimens.
Renal mRNA expression
NADPH oxidase (Nox) mRNA abundance in kidney—Relative abundance of all
isoforms of Nox mRNA were examined by real-time PCR and normalized to β-actin. In KO
mice, Nox1 and Nox2 were significantly over-expressed by ~4.7- and ~0.8-fold respectively
compared to WT mice (Fig. 3A). There were no significant differences in Nox3 or Nox4
mRNA abundance, while p22Phox (Cyba) was actually reduced in the KO by ~40%
(p=0.001)(Fig. 3A).
Other RedOx enzymes—Xdh/Xo expression was also augmented by ~0.7-fold (p=0.03)
in the KO (Fig. 3B). Sod1 was reduced in the KO by ~30% (p=0.009), as was Sod2 (by
~40%, p<0.0001), though not Sod3 (p=0.207) (Fig. 3B).
Nitric oxide synthases (Nos isoforms)—Nos3 (eNos) was increased by ~0.6-fold
(p=0.0154) in the KO; Nos1 (nNos) was increased marginally (p=0.073), while Nos2 (bNos)
was unchanged (p=0.929) (Fig. 3C).
Response of ROS to drug treatment: Clonidine or apocynin
ROS were reduced significantly in KO mice either by sympathetic inhibition (α2-agonist:
clonidine) or NADPH oxidase blockade (Nox inhibitor: apocynin).
Clonidine—Treatment with clonidine for 3 weeks reduced urinary H2O2 excretion
significantly in KO mice (from 4574.7±306.6 to 3023.4±400.4 fluorescence units/mg
creatinine, p<0.02), a value comparable to the WT level (Fig. 4A).
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Apocynin—3 weeks of apocynin also corrected the elevated urinary H2O2 excretion in KO
mice (from 4574.4±306.6 to 2389.2±376.7 fluorescence units/mg creatinine, p<0.005), once
again comparable to the WT level (Fig. 4A). In KO kidney cortex, apocynin decreased H2O2
by ~31% (on-line Fig. 1).
Response of lipid peroxidation (isoprostane) to drug treatment: Clonidine or apocynin
Elevated ROS may activate lipid peroxidation, indexed by isoprostane from arachidonic
acid. Formation of isoprostane was reduced significantly in KO mice either by sympathetic
inhibition (α2-agonist: clonidine) or NADPH oxidase blockade (Nox inhibitor: apocynin).
Clonidine—3 weeks of oral clonidine reduced urine isoprostane excretion significantly in
KO mice (from 12.86±0.61 to 9.78±0.99 ng/mg creatinine, p<0.04), which is comparable to
WT (Fig. 4B).
Apocynin—Treatment with apocynin for 3 weeks also reduced urinary isoprostane
excretion in KO mice (from 12.86±0.61 to 7.81±0.81 ng/mg creatinine, p<0.01), a final
value even lower than that seen in WT mice (10.33±0.51 vs 7.81±0.81 ng/mg creatinine,
p<0.04) (Fig. 4B).
Adrenergic over-activity: Response to drug treatment by clonidine or apocynin
In KO mice, circulating catecholamines were significantly higher than in WT
(norepinephrine: 4.22±0.50 vs 2.21±0.33 ng/ml, p<0.006; epinephrine: 1.19±0.07 vs
0.81±0.08 ng/ml, p<0.005)(Fig. 4C).
Clonidine—Treatment with clonidine corrected the elevated catecholamine levels in KO
mice (norepinephrine: from 4.22±0.50 to 2.62±0.45 ng/ml, p<0.04; epinephrine: from
1.19±0.07 to 0.90±0.10 ng/ml, p<0.04), thus returning to levels that are comparable to WT
(Fig. 4C).
Apocynin—3 weeks of apocynin also reduced catecholamine levels in KO mice
(norepinephrine: from 4.22±0.50 to 2.01±0.42 ng/ml, p<0.01; epinephrine: from 1.19±0.07
to 0.86±0.12 ng/ml, p<0.04), once a again achieving levels that are comparable to the WT
(Fig. 4C).
Nitric oxide (NO•) depletion: Response to drug treatment by clonidine or apocynin
In KO mice urine NO• excretion was reduced by ~50% as compared to WT (3273±193 vs
1546±146 μ-mol/mg creatinine, p<0.001) (Fig. 4D). In kidney cortex, NO• was reduced by
~33% in the KO (on-line Fig. 1). Likewise, KO mice also displayed a reduction of
circulating (plasma) NO• by ~23% (from 24.8±2.0 to 19.1±1.5 nmol/ml, p<0.036) (Fig. 4E).
Clonidine—Clonidine “rescued” the NO• depletion in KO mice (renal excretion: from
1546±146 to 3231±416 μmol/mg creatinine, p<0.002), which is comparable with WT (Fig.
4D). Likewise, clonidine increased circulating NO• (from 19.1±1.5 to 28.3±2.7 nmol/ml,
p<0.01), and the resulting level of NO• in plasma after clonidine treatment of KO mice was
comparable to WT (Fig. 4E).
Apocynin—After apocynin treatment in KO mice, NO• renal excretion increased (from
1546±146 to 2199±260 μ-mol/mg creatinine, p<0.039) to WT level (Fig. 4D).). In KO
kidney cortex, apocynin increased NO• by ~46% (on-line Fig. 1). Likewise, circulating NO•
concentration increased (from 19.1±1.5 to 26.2±2.6 nmol/ml, p<0.03), back to the WT level
(Fig. 4E
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Mitochondria
There was a ~28% decline in mitochondrial complex I activity in the KO animals
(normalized to citrate synthase [CS] activity, from 318±24 to 230±10 units/CS unit, p<0.03),
but no changes in the activities of complex II, complex II-III, or complex IV. Overall
mitochondrial mass, indexed by citrate synthase activity itself, was unchanged from WT to
KO (from 0.269±0.009 to 0.261±0.026 units/mg protein, p=0.79).
Discussion
Overview
Reactive oxygen species (ROS, such as H2O2 or O2− [superoxide anion]) are implicated in a
variety of cellular inflammatory responses, including pathological changes in cardiovascular
disease, aging, hypercholesterolemia, and diabetes.33 ROS synthesized by cytoplasmic/
membrane NADPH oxidases (Nox), mitochondrial NADH oxidases, or xanthine oxidase
(Xo), are to some extent unavoidable byproducts of cellular respiration. Oxygen radicals
resulting from increased ROS activity may cause cellular damage, for example in the form
of peroxidation of arachidonic acid yielding isoprostanes34, which may themselves be
vasoactive35. Elevated ROS may deplete the endogenous vasodilator NO•, thereby leading
to elevation of BP. Here we probed the role of ROS in the hyper-adrenergic hypertension
created by targeted ablation of the Chga gene15.
The sympathetic nervous system and CHGA in hypertension
Studies in animal models of genetic hypertension36 as well as investigations in hypertensive
patients13 suggest that elevated sympathoadrenal activity may play an important role in the
pathogenesis of genetically determined blood pressure elevations. CHGA (a ~48-kDa acidic
polypeptide) is targeted into the regulated secretory pathway37 and may act as an “on/off
switch” in neuroendocrine cells to trigger secretory granule biogenesis38 39, as well as the
precursor of the catecholamine release-inhibitory peptide catestatin (human CHGA 9352–372;
mouse Chga364–384)9. We developed a mouse model of targeted Chga ablation to delineate
the in vivo role of Chga. Our findings in the Chga−/− mouse confirmed the putative
functions of Chga15: Chga KO mice displayed extreme phenotypic changes including
elevated BP, loss of diurnal BP variation, and evidence of disturbed storage/release of
sympathochromaffin transmitters, with depleted adrenal but augmented plasma
concentrations. Here we uncover additional pathogenic consequences of catecholamine
excess in the model.
ROS: Role in hypertension and renal disease
While NADPH oxide-generated ROS were originally characterized biologically as “attack”
molecules in the phagocyte antimicrobial response40 or later as mediators of target organ
damage in cardio-renal or metabolic disease41, increasingly roles for ROS in autonomic
signaling have been described. For example, recent evidence suggests that NADPH oxidases
may mediate central nervous system control of sympathetic outflow42–44, and roles for
NAPDH and ROS in signal transduction for several adrenergic receptors have been
explored, including alpha-145–47, alpha-248, beta-249, and dopamine50.
Since we found ROS changes in urine and kidneys during hyper-adrenergic hypertension,
we studied ROS generation by podocytes, a renal cell type in contact with urine as it is
generated from the glomerulus in Bowman's space. In the renal podocyte51, cellular
functions (such ion currents, signal transduction) are also influenced by adrenergic agonists,
especially alpha-1 and beta-2 adrenergic agonists52,53, yielding the potential for NADPH/
ROS signaling in the podocyte (Fig. 1B), as well. The selective effect of epinephrine to
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elevate H2O2 suggests involvement of a beta-2 adrenergic receptor, while the decline by
norepinephrine suggests an action on the alpha-1 receptor32.
Source of elevated ROS in hyper-adrenergic hypertension (on-line Table 1)
We indexed ROS production principally by H2O2 excretion in urine (Fig. 1A). The net
effect of Chga−/− to elevate ROS production would seem to involve the counterbalancing
effects of several processes to both increase and decrease ROS (on-line Table 1). Two very
proximate sources of elevated ROS became likely upon studies of renal transcripts: among
Nox isoforms, Nox1 and Nox2 (phagocyte form) were elevated, despite unchanged Nox3 and
Nox4 (Renox) and an actual decline in the p22Phox (Cyba) subunit (which is shared across
Nox1/2/3/4). The Nox system is well described to catalyze the formation of superoxide
(O2−) by the pathway: 2O2− + 2H2O → 2O2‒ + H2O2 + OH−; superoxide can then dismute
(disproportionate) to H2O2 in a Sod-catalyzed pathway: 2O2− + 2H2O → O2 + H2O2 +
2OH−2. When the enzyme xanthine dehydrogenase (Xdh) is post-translationally modified to
xanthine oxidase (Xo) by reversible disulfide oxidation54,55, it then catalyzes the formation
of H2O2 by oxidation of hypoxanthine, bypassing O2− as follows: hypoxanthine + H2O + O2
→ xanthine + H2O2. Finally, even Nos itself (especially Nos3/eNos) can generate O2−,
especially when its activity is “uncoupled” by shortage of its cofactor BH4
(tetrahydrobiopterin)56.
Thus, at least three potential sources of ROS excess in Chga−/− emerge from transcriptional
studies: elevations in mRNAs for Nox1/Nox2 (Fig. 3A), Xdh/XO and Nos3/eNos (since
Nos3/eNos may give rise to O2− when “uncoupled”) (Fig. 3B). Furthermore, depletion of
Sod1/Sod2 (Fig. 3B) would tend to sustain the duration of action of any ROS generated.
Apocynin inhibits Nox activity by interfering with the assembly of the Nox monomers into
the final heteromultimeric active complex; normalization of elevated ROS by apocynin (Fig.
4A&B) further implicates the Nox pathway in the excess ROS state of Chga−/−; although
apocynin is a relatively low potency inhibitor of Nox4 (Renox)57, the transcript abundance
studies (Fig. 3A) suggest that, within Nox pathways, apocynin-sensitive isoforms Nox1/
Nox2 are principally at work in the Chga−/− state.
At least two transcriptional changes would tend to decrease ROS in the Chga−/− state:
decreased p22Phox/Cyba mRNA (since p22Phox is a shared subunit among Nox1–4
isoforms), and increased catalase/Cat mRNA (since catalase catalyzes the reaction: 2 H2O2
→ 2 H2O + O2)
Although mitochondria can also generate ROS, particularly O2− arising through incomplete
NADH-mediated reduction of O2 in complex I (by NADH dehydrogenase) or complex III
(by coenzyme Q/cytochrome c reductase), here we found that overall mitochondrial mass
was unchanged, and the activity of complex I was actually reduced (p<0.03), while the
activities of complex II, complex II–III, or complex IV were unchanged. This reduction in
complex I activity would have the effect of decreasing the electron flow and superoxide
production in mitochondria, and may be seen as compensatory to increased superoxide
production by Nox1/2.
Origin of NO• depletion in hyper-adrenergic hypertension
A likely scenario is that O2− generated by Nox activation (2O2 + 2H2O → 2O2− + H2O2 +
OH−) then depletes NO• by forming peroxynitrite (O2− + NO• → ONO2−). H2O2 can also
react with NO• to produce singlet oxygen.58, 59 While our measurements of NO• were
indirect (NO• → NO2 → NO3 quantified by the colorimetric Griess reaction), the results
were directionally coordinate in urine and plasma (Fig. 4D&E), and consistent with known
responses of NO• to oxygen radicals.
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By contrast, the enzymatic sources of NO•, Nos1/2/3, did not appear to be depleted in the
KO, at least at a transcriptional level: the renal transcript for Nos3 (eNos) was actually
increased in the Chga−/− mouse (p=0.0154), while Nos1 and Nos2 transcripts were
unchanged (Fig. 3C). Nos enzymes are subject to post-translational modifications60, and we
have no direct evidence to exclude post-translational inactivation of Nos enzymes. However,
in the face of diminished NO• in the KO (Fig. 4D&E), a predicted decline in Nos
nitrosylation would be expected to increase Nos enzymatic activity60; likewise, elevated
catecholamines in the KO (Fig. 4C) would be predicted to signal through protein kinases A
and B to Nos phosphorylation and hence enzymatic activation61. Thus, it would be difficult
to invoke known signaling pathways to postulate post-translational inactivation of Nos
enzymes.
Treatment implications
Both sympathetic outflow inhibition with clonidine and NADPH oxidase inhibition with
apocynin seemed to normalize the diverse phenotypes deranged in the Chga−/− state,
including increased DBP, ROS excess, lipid peroxidation, catecholamine elevation, and NO•
depletion (Fig. 4A–E). Since the Chga−/− model displays many features in common with
human hypertension, and common genetic variation at the human CHGA locus predicts
changes in BP12, 13, these treatment results may prompt novel therapeutic strategies for
human hypertension. Of note for pathophysiology, both agents (clonidine and apocynin)
normalized not only DBP, but also ROS and catecholamine excess. These findings suggest
that there may be bidirectional or reciprocal influences of catecholamines and ROS on each
other's production. Why did clonidine and apocynin normalize DBP though not SBP in
Chga−/− mice (Fig 2)? We evaluated only one dose for each drug, and cannot exclude the
possibility that greater doses would normalize SBP as well. Alternatively, SBP elevations in
the face of chronic (5–6 month) hypertension may involve structural adaptations of large
arteries that cannot be completely reversed by only 3 weeks of treatment. Finally, the SBP
elevation in Chga−/− mice may involve additional mechanisms that cannot be completely
reversed by sympathetic outflow or NADPH inhibition.
Advantages and limitations to this study
Our experiments took advantage of a definitive biological reagent for evaluation of the
consequences of Chga: i.e., the Chga−/− mouse. In this system, we were able to probe a
spectrum of properties of the strain: molecular/transcriptional (mRNA profiling),
biochemical (ROS, catecholamines, NO•, isoprostane), physiological (BP), and
pharmacological (sympathetic blockade with clonidine, Nox blockade with apocynin).
While our experiments point to a unifying explanation (Fig. 5) for the diverse adrenergic,
oxidative, and nitroxidergic manifestations of the hypertension consequent upon Chga
ablation, the work does raise new questions, both methodological and conceptual. We
identified changes in several transcripts that might account for the oxidative consequences
of Chga: Nox1/2, Xdh/Xo, Sod1/2, Nos3, and Cat. however, we do not yet understand the
relative quantitative contributions of these gene products to the altered oxidative state in
Chga−/− hypertension.
Clonidine acts centrally to effectively reduce sympathetic outflow (Fig. 4A–E), as evidenced
by substantial reductions of elevated epinephrine and norepinephrine; however, we have not
characterized the particular target-organ adrenergic receptors by which the elevated
catecholamines exert their oxidative and nitroxidergic consequences, though the selective
action of epinephrine (but not norepinephrine) to elevate podocyte H2O2 production (Fig.
1B, 1C) may implicate beta-2 (ADRB2) receptor subtypes32. Nor do we yet understand
precisely how catecholamines' post-receptor signal transduction apparatus (heterotrimeric
Gayen et al. Page 10
Circ Cardiovasc Genet. Author manuscript; available in PMC 2011 October 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
GTP-binding [“G”] proteins) might contact and influence expression of Nox, Nos, or Sod
isoforms, or Xdh/Xo.
Catecholamines themselves can undergo base-catalyzed, non-enzymatic auto-oxidation,
thereby generating ROS; indeed, antioxidant drugs may ameliorate catecholamine-mediated
organ toxicity in some settings62. However, catecholamine oxidation is quite slow at
physiological pH63, and plasma catecholamine concentrations are typically only in the high
fM to pM range. In addition, catecholamine metabolism via monoamine oxidase (MAO)
proceeds by oxidative deamination, yielding H2O264. However, others have shown that
ROS-mediated responses to catecholamines are mediated by adrenergic receptors65, 66.
Finally, we used the inhibitor apocynin to probe the role of Nox in these processes, since
aopocynin is known to interfere with assembly of Nox monomers into active
heteromultimeric enzymatic complexes; while apocynin has the advantages of previous
characterization of its particular Nox enzymatic isoform targets57, and tolerability with
administration in vivo (here, 3 weeks at 2 mM in drinking water), a recent report suggests
that apocynin may have other effects on oxidative pathways, such as a direct antioxidant
(electron donor) property67.
Nonetheless, hypertension is perhaps the quantitatively most potent risk factor for
cardiovascular disease68, and since common genetic variation at the CHGA locus has
substantial effects on BP in humans12–14, our results are likely to have implications for not
only the pathogenesis but also the target organ consequences of human hypertension.
Conclusions and perspectives
Dysregulated ROS production has the potential to “hijack” physiological excitatory
pathways (especially in brain) to elevate BP43. Such changes in ROS may result from
catecholaminergic signaling42–50 (Fig. 1B&C); thus, the catecholamine excess resulting
from decline in Chga expression15 (Fig. 4C) may initiate the pathogenic ROS cascade (Fig.
5), in processes that are both transcriptional (Fig. 3) and at a level not requiring new mRNA
or protein synthesis (Fig. 1B). Pharmacological disruption of this cascade, at the level of
either sympathetic outflow or ROS synthesis, not only corrects disturbances in ROS (Fig.
4A&B) and NO• (Fig. 4D&E) production, but also normalizes elevated BP. Our results thus
point to a role for novel pathways in the genesis and consequences of hypertension, and
suggest new strategies for approaching the pathogenesis and treatment of hypertension, as
well as the amelioration of its target organ consequences.
Oxidative stress, in which reactive oxygen species (ROS) outstrip antioxidant defenses,
contributed to cardiovascular disease. In the present investigation, we studied
derangements of ROS in the development of a hyper-adrenergic model of hereditary
hypertension: targeted ablation (knockout, KO) of chromogranin A (Chga) in the mouse.
In the KO mouse, BP elevation was accompanied by not only catecholamine excess, but
also by increased ROS (H2O2) and isoprostane levels (index of lipid peroxidation). Renal
transcript analyses implicated changes in several redox enzymes. KO alterations in BP as
well as biochemical traits could be abrogated by inhibition of either sympathetic outflow
or of NADPH oxidase. In cultured renal podocytes, H2O2 production was augmented by
epinephrine (likely through beta-2-receptors). Thus, ROS may play an important role in
the development of hyper-adrenergic hypertension in this experimental model, in a
process mechanistically linking elevated BP with catecholamine excess, renal
transcriptional responses, ROS elevation, lipid peroxidation, and NO• depletion. Overall,
our results demonstrate the existence of novel pathophysiological links between the
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adrenergic system and oxidative stress, and suggest new strategies to probe the role and
actions of ROS in this setting.
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Figure 1.
A. Chga targeted ablation on H2O2 and lipid peroxidation (isoprostane). Urine isoprostane
and H2O2 measured and normalized by creatinine. WT vs KO: H2O2 (p<0.02) and
isoprostane (p<0.002), [n=6 animals/condition]. Results are shown as mean ± one SEM. B.
Renal podocytes, catecholamines and H2O2. Catecholamines (both epinephrine and
norepinephrine; each at 1 μM) were used to influence H2O2 production in mouse podocytes
(n=6 replicate wells per condition). Results are shown as mean ± one SEM. C. Selective
adrenergic agonists and renal podocyte H2O2. Selective adrenergic agonists (alpha-1:
phenylephrine; alpha-2: clonidine; beta: isoproterenol), each at 1 μM, were used to influence
H2O2 production in mouse podocytes (n=6 replicate wells per condition). Results are shown
as mean ± one SEM.
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Figure 2. Adrenergic outflow inhibition (clonidine) or NADPH oxidase (Nox) inhibition
(apocynin) on BP
Both SBP and DBP were reduced significantly in KO mice by sympathetic inhibition with
the α2-agonist clonidine (125 μg/kg body weight/day for 3 weeks). SBP and DBP were
reduced significantly in KO mice by Nox inhibitor apocynin (2 mmol/L) in drinking water
for 3 weeks. N for each group (number of mice) is given in the figure inset. Results are
shown as mean ± one SEM.
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Figure 3. mRNA abundances in kidney
Relative abundances of mRNAs were normalized to β-actin in kidney by real-time PCR
(n=12 kidneys were studied from each strain, WT or KO). Differences in Ct (target mRNA
versus β-actin mRNA) are expressed on a % scale (see Methods). Results are shown as
mean ± one SEM. A. NADPH oxidase (Nox) isoforms. B. RedOx targets. C. Nos (nitric
oxide synthase) isoforms.
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Figure 4A. Oxygen radicals (H2O2): Response to treatment by sympathetic inhibition or
NADPH oxidase blockade
Urine H2O2 level (amplex red fluorescence/mg creatinine) is presented in WT (n=6), KO
(n=6), KO+clonidine (n=8), or KO+apocynin (n=8) mice. Results are shown as mean ± one
SEM. B. Lipid peroxidation (isoprostane): Response to treatment by sympathetic inhibition
or NADPH oxidase (Nox) blockade. Urine isoprostane level (ng/mg creatinine) is presented
in WT (n=6), KO (n=6), KO+clonidine (n=8), or KO+apocynin (n=8) mice. Results are
shown as mean ± one SEM. C. Catecholamine secretion: Response to treatment by
sympathetic inhibition or NADPH oxidase (Nox) blockade. Plasma catecholamine levels
(ng/ml) of WT, KO, KO+clonidine and KO+apocynin mice [n=8 per condition] were
measured by HPLC, in plasma obtained from anesthetized mice. Results are shown as mean
± one SEM. D. Nitric oxide (NO•) depletion: Response to treatment by sympathetic
inhibition or NADPH oxidase (Nox) blockade. Urinary excretion of nitrate+nitrite was taken
as an index of NO• production. Urine levels of NO• (μmol/mg creatinine) were measured in
WT (n=5), KO (n=8), KO+clonidine (n=7) and KO+apocynin (n=7) mice. Results are
shown as mean ± one SEM. E. Nitric oxide (NO•) depletion in the circulation: Response to
treatment by sympathetic inhibition or NADPH oxidase (Nox) blockade. Plasma levels of
NO• (nmol/ml) were measured in WT (n=10), KO (n=10), KO+clonidine (n=8). and KO
+apocynin (n=8) mice. Results are shown as mean ± one SEM.
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Figure 5. Oxygen radicals and hyper-adrenergic hypertension: Hypothesis integrating
experimental results from this study in targeted ablation of the mouse Chga locus
Directional arrows indicate proposed cause-and-effect relationships.
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